Rani Therapeutics Holdings, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: RANI · Form: DEF 14A · Filed: Apr 17, 2024 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | DEF 14A |
| Filed Date | Apr 17, 2024 |
| Risk Level | |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy statement, annual meeting, stockholders, directors, auditor
TL;DR
<b>Rani Therapeutics Holdings, Inc. will hold its virtual Annual Meeting of Stockholders on May 29, 2024, to elect directors and ratify the appointment of its auditor.</b>
AI Summary
Rani Therapeutics Holdings, Inc. (RANI) filed a Proxy Statement (DEF 14A) with the SEC on April 17, 2024. Annual Meeting of Stockholders scheduled for May 29, 2024, at 8:00 a.m. Pacific Time. Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/RANI2024. Stockholders cannot attend the meeting in person. Purpose 1: Election of eight director nominees. Purpose 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024.
Why It Matters
For investors and stakeholders tracking Rani Therapeutics Holdings, Inc., this filing contains several important signals. The virtual format requires stockholders to access the meeting online, necessitating attention to login procedures and control numbers. The election of directors and ratification of the auditor are standard corporate governance procedures crucial for company oversight and financial integrity.
Risk Assessment
Risk Level: — Rani Therapeutics Holdings, Inc. shows moderate risk based on this filing. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy statement for details on director nominees and the proposed auditor before the May 29, 2024 meeting.
Key Numbers
- 8 — Director Nominees (Number of director nominees to be elected at the meeting.)
- May 29, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders.)
- 8:00 a.m. Pacific Time — Meeting Time (Time the Annual Meeting will commence.)
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant and filer of the proxy statement.
- May 29, 2024 (date) — Date of the Annual Meeting of Stockholders.
- Ernst & Young LLP (company) — Proposed independent registered public accounting firm.
- December 31, 2024 (date) — Fiscal year end for which the auditor is being ratified.
FAQ
When did Rani Therapeutics Holdings, Inc. file this DEF 14A?
Rani Therapeutics Holdings, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 17, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Rani Therapeutics Holdings, Inc. (RANI).
Where can I read the original DEF 14A filing from Rani Therapeutics Holdings, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Rani Therapeutics Holdings, Inc..
What are the key takeaways from Rani Therapeutics Holdings, Inc.'s DEF 14A?
Rani Therapeutics Holdings, Inc. filed this DEF 14A on April 17, 2024. Key takeaways: Annual Meeting of Stockholders scheduled for May 29, 2024, at 8:00 a.m. Pacific Time.. Meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/RANI2024.. Stockholders cannot attend the meeting in person..
Is Rani Therapeutics Holdings, Inc. a risky investment based on this filing?
Based on this DEF 14A, Rani Therapeutics Holdings, Inc. presents a moderate-risk profile. This filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Rani Therapeutics Holdings, Inc.'s DEF 14A?
Stockholders should review the proxy statement for details on director nominees and the proposed auditor before the May 29, 2024 meeting. The overall sentiment from this filing is neutral.
How does Rani Therapeutics Holdings, Inc. compare to its industry peers?
Rani Therapeutics Holdings, Inc. operates in the pharmaceutical preparations industry, focusing on developing novel drug delivery systems.
Are there regulatory concerns for Rani Therapeutics Holdings, Inc.?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
Industry Context
Rani Therapeutics Holdings, Inc. operates in the pharmaceutical preparations industry, focusing on developing novel drug delivery systems.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
What Investors Should Do
- Review the list of director nominees and their qualifications.
- Evaluate the proposal to ratify Ernst & Young LLP as the independent auditor.
- Ensure access to the virtual meeting platform and understand the voting process.
Key Dates
- 2024-05-29: Annual Meeting of Stockholders — Election of directors and ratification of auditor.
Year-Over-Year Comparison
This is a DEF 14A filing for the annual meeting, providing information on upcoming corporate governance decisions.
Filing Stats: 4,731 words · 19 min read · ~16 pages · Grade level 11.7 · Accepted 2024-04-17 08:00:38
Filing Documents
- ny20018840x1_def14a.htm (DEF 14A) — 732KB
- ny20018840x1_pc01.jpg (GRAPHIC) — 574KB
- ny20018840x1_pc02.jpg (GRAPHIC) — 601KB
- sig_timran.jpg (GRAPHIC) — 24KB
- 0001140361-24-020199.txt ( ) — 2384KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 18 EXECUTIVE OFFICERS ​ ​ 20 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS ​ ​ 21
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 22 Summary Compensation Table ​ ​ 22 Outstanding Equity Awards at Fiscal Year End ​ ​ 23 Clawbacks ​ ​ 25 Potential Payments Upon Termination or Change in Control ​ ​ 26 Director Compensation ​ ​ 27 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION ​ ​ 29 Related Person Transactions Policy and Procedures ​ ​ 29 Certain Related Person Transactions ​ ​ 29 Indemnification ​ ​ 31 HOUSEHOLDING OF PROXY MATERIALS ​ ​ 33 OTHER MATTERS ​ ​ 34 TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the “SEC”), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the “Notice”) because the Board of Directors of Rani Therapeutics Holdings, Inc. (sometimes referred to as “Rani Holdings”, and together with its subsidiary, Rani Therapeutics, LLC (“Rani LLC”), as “us”, “our, “we” and the “Company”) is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about April 17, 2024 to all stockholders of record entitled to vote at the annual meeting. Will